Cardinal Health (CAH) Stock
US healthcare distributor of drugs and medical products. Here's the price, business snapshot, and what's worth knowing about Cardinal Health in August 2026.
Cardinal Health, Inc. (CAH) is a major US healthcare services and products company, with a market capitalisation near $37.7 billion. It operates large-scale pharmaceutical distribution and supplies medical-surgical products to hospitals, pharmacies and clinics, while also developing higher‑margin device and services offerings. Investors should know the business combines high-volume, low-margin distribution with targeted growth in medical products, so operational efficiency, inventory management and contract terms are key profit levers. The company faces sector-specific risks including reimbursement pressure, hospital budget cycles, regulatory scrutiny and strong competition from peers. Recent strategic emphasis has been on margin improvement, specialty products and supply-chain resilience, though execution and healthcare demand trends will matter. This is general educational information, not personalised advice; values can rise or fall and past performance is no guarantee of future results. Consider how exposure to healthcare distribution fits your risk tolerance and investment horizon before acting.
Why It’s Moving
Cardinal Health climbs on a stronger profit outlook, but analysts still see limited upside room.
- Cardinal Health jumped after fiscal Q4 and full-year 2026 results showed stronger profitability, with adjusted EPS beating expectations and full-year cash generation reinforcing execution quality.
- The company’s FY2027 outlook came in above consensus, signaling management expects the momentum in pharmaceutical and specialty distribution to carry into the new year.
- A fresh dividend announcement and expanded buyback authorization added to the shareholder-return story, helping support the stock even as revenue missed top-line estimates.
Cardinal Health climbs on a stronger profit outlook, but analysts still see limited upside room.
- Cardinal Health jumped after fiscal Q4 and full-year 2026 results showed stronger profitability, with adjusted EPS beating expectations and full-year cash generation reinforcing execution quality.
- The company’s FY2027 outlook came in above consensus, signaling management expects the momentum in pharmaceutical and specialty distribution to carry into the new year.
- A fresh dividend announcement and expanded buyback authorization added to the shareholder-return story, helping support the stock even as revenue missed top-line estimates.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for CAH is expected on October 29, 2026. This report should cover fiscal first-quarter 2027 results. The timing is based on Cardinal Health’s historical reporting pattern, and the company has not yet formally confirmed the date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardinal Health's stock, believing it has significant potential for growth.
Financial Health
Cardinal Health is generating substantial sales and cash flow, but its profit margins are low.
Dividend
Cardinal Health's dividend yield of 0.77% is lower, indicating limited returns for dividend-seeking investors. If you invested $1000 you would be paid $7.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Scale & Distribution
A wide distribution network underpins revenue through volume, but margins are typically thin so operational efficiency is essential.
Higher‑Margin Push
Growth in medical devices and services aims to lift margins, though execution risk and competitor response are important considerations.
Regulation & Cycles
Reimbursement trends, hospital spending cycles and regulatory changes can materially affect performance, and returns may vary over time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.